|
**Overview**: Hemoglobinopathy Newborn Panel**Introduction**: The Hemoglobinopathy Newborn Panel is a diagnostic tool designed for newborn hemoglobinopathy screening using whole blood samples. In India, hemoglobinopathies (beta-thalassemia major, sickle cell disease) affect ~100,000 newborns annually (~40 million carriers), with high prevalence in tribal and northern regions. Early screening prevents severe anemia, transfusion dependence, and mortality. High burden from under-screening in rural/low-SES newborns, limited newborn screening programs, delayed diagnosis leading to growth failure or death by age 5 in untreated thalassemia major. Per hematology practices aligned with ICMR and National Thalassemia Control Programme guidelines, the test employs electrophoresis for HbF, HbA, HbS, HbC over 1-2 days with high accuracy, valuable for identifying major hemoglobinopathies at birth. This diagnostic falls under newborn screening and targets all newborns (universal in high-prevalence areas), addressing accurate detection to guide early transfusion/chelation or genetic counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling timely intervention and reducing hemoglobinopathy mortality. Its whole blood-based approach ensures reliable variant identification.**Other Names**: Hb Newborn Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/molecular pathology, compliant with 2025 standards.**Historical Milestone**: Newborn Hb screening expanded; in India, piloted in high-prevalence states.**Purpose**: The test assesses 4 parameters including HbF to guide newborn hemoglobinopathy screening, detect major variants, inform early management.**Test Parameters**: 1. HbF, 2. HbA, 3. HbS, 4. HbC.**Pretest Condition**: No fasting required; patients should be newborns.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for electrophoresis).**Medical History**: Parents should provide details on ethnicity, family history of anemia.**Consent**: Written informed consent from parents is required, detailing the test's purpose, potential risks of undetected hemoglobinopathy including severe anemia, benefits of early detection, and minimal discomfort from heel prick/blood draw.**Procedural Considerations**: The test involves sample processing using electrophoresis by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent transfusion can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal Hb pattern indicates hemoglobinopathy, necessitating specialist input. Normal may require follow-up in high-risk.**Specialist Consultation**: Pediatric hematologists should be consulted for management.**Additional Supporting Tests**: DNA analysis, HPLC for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Hemoglobinopathy Studies India 2023. |
